Delivering Transformative Therapies and Advancing Health Equity
Through innovation, we’re helping to build a healthier world for all people.
Learn More About GileadMedicines Offered Globally
Clinical Programs Across Virology, Oncology and Inflammation
Funder of HIV Causes in the U.S.
Using Science to Improve the Lives of People and Communities
We invest in world-class science to combat the world's most devastating diseases.
Explore ScienceA Strong Pipeline Spanning Three Therapeutic Areas
We have a deep, diverse pipeline across Virology, Oncology and Inflammation.
View Our PipelineAn Inclusive Workplace Where We All Can Make an Impact
More than 18,000 employees at Gilead worldwide work to advance scientific innovation, help ensure our medicines reach those who need it and make a difference in the communities where we live and work.
Explore Careers at GileadNews
Some of the content on this page is not intended for users outside the U.S.
Gilead Sciences to Present at Upcoming Investor Conference
December 20, 2024U.S. FDA Grants Breakthrough Therapy Designation to Trodelvy® (sacituzumab govitecan-hziy) for Second-Line Treatment of Extensive-Stage Small Cell Lung Cancer
December 17, 2024Gilead and Terray Therapeutics Announce Multi-Target Research Collaboration to Discover and Develop Novel Small Molecule Therapies
December 17, 2024Gilead’s Seladelpar Receives Positive CHMP Opinion for Primary Biliary Cholangitis
December 13, 2024Gilead Sciences Appoints Dietmar Berger, MD, PhD, as Chief Medical Officer
December 12, 2024Kite’s Yescarta® Only CAR T-Cell Therapy to Show Durable Response and Long-Term Survival After Five Years in Patients With Relapsed/Refractory Non-Hodgkin Lymphomas at ASH 2024
December 09, 2024
Investors